NFKB1 and cancer: Similarly, proteasome inhibitors with clinical indication in MM, such as bortezomib, inhibit many essential cellular pathways that rely on proteasome function, among which is the NF-κB pathway, and, furthermore, target these pathways in normal and cancer cells alike, thus resulting in a low therapeutic index and dose-limiting toxicities (Richardson, 2010, Chen et al., 2011).